Joseph Michael Fitzgerald - 03 Mar 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: EVP & Pres, Cardiology
Signature: /s/ Susan Thompson, Attorney-in-Fact
Issuer symbol: BSX
Transactions as of: 03 Mar 2022
Transactions value $: -$78,205
Form type: 4
Filing time: 07 Mar 2022, 15:21:22 UTC
Previous filing: 24 Feb 2022
Next filing: 14 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BSX	Common Stock	Options Exercise	$0	+3.6K	+1.67%	$0.00	220K	03 Mar 2022	Direct	F1
transaction	BSX	Common Stock	Tax liability	-$78.2K	-1.78K	-0.81%	$43.96	218K	03 Mar 2022	Direct
holding	BSX	Common Stock						68.2K	03 Mar 2022	By 401(k)	F2
holding	BSX	Common Stock						7.43K	03 Mar 2022	By Children	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Deferred Stock Units	Options Exercise	$0	-3.6K	-100%	$0.00^*	0	03 Mar 2022	Common Stock	3.6K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2	Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3	The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.
F4	Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.